DENOMINATOR: All patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis
|
|
- Donald Merritt
- 10 months ago
- Views:
Transcription
1 Quality ID #401: Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION: Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis who underwent imaging with either ultrasound, contrast enhanced CT or MRI for hepatocellular carcinoma (HCC) at least once within the 12 month reporting period INSTRUCTIONS: This measure is to be submitted a minimum of once per performance period for all patients with a diagnosis of chronic hepatitis C cirrhosis seen during the performance period. This measure is intended to reflect the quality of services provided for patients with chronic hepatitis C cirrhosis. This measure may be submitted by eligible clinicians or other qualified healthcare professionals who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding. Measure Submission: The listed denominator criteria is used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions allowed by the measure. The quality-data codes listed do not need to be submitted for registry submissions; however, these codes may be submitted for those registries that utilize claims data. DENOMINATOR: All patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis Denominator Criteria (Eligible Cases): Patients aged 18 years on date of encounter AND Diagnosis for chronic hepatitis C (ICD-10-CM): B18.2, B19.20, B19.21 AND Diagnosis for cirrhosis (ICD-10-CM): K70.30, K70.31, K74.60, K74.69 AND Patient encounter during the performance period (CPT): 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, NUMERATOR: Patients who underwent abdominal imaging with either ultrasound, contrast enhanced CT or MRI OR Numerator Options: Performance Met: Patient underwent abdominal imaging with ultrasound, contrast enhanced CT or contrast MRI for HCC (G9455) Page 1 of 6
2 OR Denominator Exception: Performance Not Met: Documentation of medical or patient reason(s) for not ordering or performing screening for HCC. Medical reason: Comorbid medical conditions with expected survival <5 years, hepatic decompensation and not a candidate for liver transplantation, or other medical reasons. Patient reasons: Patient declined or other patient reasons (e.g., cost of tests, time related to accessing testing equipment) (G9456) Patient did not undergo abdominal imaging and did not have a documented reason for not undergoing abdominal imaging in the reporting period (G9457) RATIONALE: HCC (hepatocellular carcinoma) is the fourth most common cancer in the world and is the fastest rising cause of cancer-related deaths in the United States. HCV is the leading cause of HCC and the risk of developing HCC is highest in patients with established HCV cirrhosis. Several potentially curative treatments are available for patients with early-stage HCC. These include surgical resection, liver transplantation, and local ablation. Long-term survival of patients who have liver resection or transplantation for HCC can be high (40% to 70% for resection and 52% to 81% for transplant patients after 5 years) (Kansagara 2014). A recent systematic review of 18 nonrandomized studies found that screened patients had early-stage HCC than clinically diagnosed patients. More screened patients received potentially curative treatment. However, these studies were limited by their observational nature (including lead time bias) and thus the effect on overall mortality was unclear. There are no randomized controlled trials that evaluated the impact of HCC screening versus no screening on survival in patients with cirrhosis. A randomized trial of HCC screening is not forthcoming because, even in the absence of high quality data, most informed patients and their clinicians consider randomization unethical and prefer surveillance (Poustchi 2011). In a recent modeling based study (that corrected for lead time bias), US based screening for HCC in compensated HCV cirrhosis patients reduced mortality compared to no screening (Mourad 2014). Collectively, these data suggest that screening has a potential to produce benefits in the highest-risk patients, such as those with HCV cirrhosis who are good candidates for potentially curative treatment (Atkins AIM 2014). CLINICAL RECOMMENDATION STATEMENTS: Patients at high risk for developing HCC, including patients with hepatitis C cirrhosis, should be entered into surveillance programs. (Level II). Surveillance for HCC should be performed using ultrasonography (Level II). Patients should be screened at 6-month intervals (level II) (AASLD, 2011). HCC surveillance must be continued indefinitely in patients with cirrhosis (A1). Patients with cirrhosis should undergo regular surveillance for HCC, irrespective of SVR (B1) (EASL, 2014) While current guidelines only specify using ultrasound, evidence suggests that using multiple screening methods, including incorporating the alpha fetoprotein biomarker into surveillance plans, may be more effective in identifying early stages of HCC. COPYRIGHT: The Measures are not clinical guidelines, do not establish a standard of medical care, and have not been tested for all potential applications. Page 2 of 6
3 The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, eg, use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and the American Medical Association (AMA), [on behalf of the Physician Consortium for Performance Improvement (PCPI )] or American Gastroenterological Association (AGA). Neither the AMA, AGA, PCPI, nor its members shall be responsible for any use of the Measures. The AMA s and PCPI s significant past efforts and contributions to the development and updating of the Measures is acknowledged. AGA is solely responsible for the review and enhancement ( Maintenance ) of the Measures as of June 30, AGA encourages use of the Measures by other health care professionals, where appropriate. THE MEASURES AND SPECIFICATIONS ARE PROVIDED AS IS WITHOUT WARRANTY OF ANY KIND American Medical Association and American Gastroenterological Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use. Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, AGA, the PCPI and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT ) or other coding contained in the specifications. CPT contained in the Measures specifications is copyright American Medical Association. LOINC copyright Regenstrief Institute, Inc. SNOMED CLINICAL TERMS (SNOMED CT ) copyright College of American Pathologists. All Rights Reserved. Page 3 of 6
4 Page 4 of 6
5 2018 Registry Flow for Quality ID #401 Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis Please refer to the specific section of the Measure Specification to identify the denominator and numerator information for use in submitting this Individual Specification. This flow is for registry-data submission. 1. Start with Denominator 2. Check Patient Age: a. If the Age is greater than or equal to 18 Years on Date of Service and equals No during the measurement period, do not include in Eligible Patient Population. Stop Processing. b. If the Age is greater than or equal to 18 Years on Date of Service and equals Yes during the measurement period, proceed to check Patient Diagnosis. 3. Check Patient Diagnosis Chronic Hepatitis C: a. If Diagnosis of Chronic Hepatitis C as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing. b. If Diagnosis of Chronic Hepatitis C as Listed in the Denominator equals Yes, proceed to check Patient Diagnosis Cirrhosis. 4. Check Patient Diagnosis Cirrhosis: a. If Diagnosis for Cirrhosis as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing. b. If Diagnosis for Cirrhosis as Listed in the Denominator equals Yes, proceed to check Encounter Performed. 5. Check Encounter Performed: a. If Encounter as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing. b. If Encounter as Listed in the Denominator equals Yes, include in the Eligible Population. 6. Denominator Population: a. Denominator population is all Eligible Patients in the denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 80 patients in the Sample Calculation. 7. Start Numerator 8. Check Patient Underwent Abdominal Imaging with Ultrasound, Contrast Enhanced CT or Contrast MRI for HCC: a. If Patient Underwent Abdominal Imaging with Ultrasound, Contrast Enhanced CT or Contrast MRI for HCC equals Yes, include in Data Completeness Met and Performance Met. Page 5 of 6
6 b. Data Completeness Met and Performance Met is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a equals 40 patients in Sample Calculation. c. If Patient Underwent Abdominal Imaging with Ultrasound, Contrast Enhanced CT or Contrast MRI for HCC equals No, proceed to Documentation of Medical or Patient Reason(s) for Not Ordering or Performing Screening for HCC. 9. Check Documentation of Medical or Patient Reason(s) for Not Ordering or Performing Screening for HCC: a. If Documentation of Medical or Patient Reason(s) for Not Ordering or Performing Screening for HCC equals Yes, include in Data Completeness Met and Denominator Exception. b. Data Completeness Met and Denominator Exception is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter b equals 10 patients in the Sample Calculation. c. If Documentation of Medical or Patient Reason(s) for Not Ordering or Performing Screening for HCC equals No, proceed to Patient Did Not Undergo Abdominal Imaging and Did Not Have a Documented Reason for Not Undergoing Abdominal Imaging in the Reporting Period. 10. Check Patient Did Not Undergo Abdominal Imaging and Did Not Have a Documented Reason for Not Undergoing Abdominal Imaging in the Reporting Period: a. If Patient Did Not Undergo Abdominal Imaging and Did Not Have a Documented Reason for Not Undergoing Abdominal Imaging in the Reporting Period equals Yes, include in Data Completeness Met and Performance Not Met. b. Data Completeness Met and Performance Not Met is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter c equals 20 patients in the Sample Calculation. c. If Patient Did Not Undergo Abdominal Imaging and Did Not Have a Documented Reason for Not Undergoing Abdominal Imaging in the Reporting Period equals No, proceed to Data Completeness Not Met. 11. Check Data Completeness Not Met: a. If Data Completeness Not Met equals No, Quality Data Code or equivalent was not submitted. 10 patients have been subtracted from the Data Completeness Numerator in the Sample Calculation. SAMPLE CALCULATIONS: Data Completeness= Performance Met (a=40 patients) + Denominator Exception (b=10 patients) + Performance Not Met (c=20 patients) = 70 patients = 87.50% Eligible Population / Denominator (d=80 patients) = 80 patients Performance Rate= Performance Met (a=40 patients) = 40 patients = 66.67% Data Completeness Numerator (70 patients) - Denominator Exception (b=10 patients) = 60 patients Page 6 of 6
2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Measure #109: Osteoarthritis (OA): Function and Pain Assessment National Quality Strategy Domain: Person and Caregiver-Centered Experience and Outcomes 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
Quality ID #225 (NQF 0509): Radiology: Reminder System for Screening Mammograms National Quality Strategy Domain: Communication and Care Coordination
Quality ID #225 (NQF 0509): Radiology: Reminder System for Screening Mammograms National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
DENOMINATOR: All female patients aged 65 years and older with a visit during the measurement period
Measure #48: Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR
2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Measure #143 (NQF 0384): Oncology: Medical and Radiation Pain Intensity Quantified National Quality Strategy Domain: Person and Caregiver-Centered Experience and Outcomes 2017 OPTIONS FOR INDIVIDUAL MEASURES:
Measure #265: Biopsy Follow-Up National Quality Strategy Domain: Communication and Care Coordination
Measure #265: Biopsy Follow-Up National Quality Strategy Domain: Communication and Care Coordination 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION: Percentage of
Quality ID #6 (NQF 0067): Coronary Artery Disease (CAD): Antiplatelet Therapy National Quality Strategy Domain: Effective Clinical Care
Quality ID #6 (NQF 0067): Coronary Artery Disease (CAD): Antiplatelet Therapy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process
2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #440: Basal Cell Carcinoma (BCC)/Squamous Cell Carcinoma (SCC): Biopsy Reporting Time Pathologist to Clinician National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS
Quality ID #110 (NQF 0041): Preventive Care and Screening: Influenza Immunization National Quality Strategy Domain: Community/Population Health
Quality ID #110 (NQF 0041): Preventive Care and Screening: Influenza Immunization National Quality Strategy Domain: Community/Population Health 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE
Measure #76: Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections National Quality Strategy Domain: Patient Safety
Measure #76: Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections National Quality Strategy Domain: Patient Safety 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE:
DENOMINATOR: All female patients aged 65 years and older with a visit during the measurement period
Measure #48: Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR
DENOMINATOR: All female patients aged 65 years and older with a visit during the measurement period
Quality ID #48: Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR
Measure #69 (NQF 0380): Hematology: Multiple Myeloma: Treatment with Bisphosphonates National Quality Strategy Domain: Effective Clinical Care
Measure #69 (NQF 0380): Hematology: Multiple Myeloma: Treatment with Bisphosphonates National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE
Measure #279: Sleep Apnea: Assessment of Adherence to Positive Airway Pressure Therapy National Quality Strategy Domain: Effective Clinical Care
Measure #279: Sleep Apnea: Assessment of Adherence to Positive Airway Pressure Therapy National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE
Measure #282: Dementia: Functional Status Assessment National Quality Strategy Domain: Effective Clinical Care
Measure #282: Dementia: Functional Status Assessment National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION: Percentage
2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome
Quality ID #410: Psoriasis: Clinical Response to Oral Systemic or Biologic Medications National Quality Strategy Domain: Person and Caregiver-Centered Experience and Outcomes 2018 OPTIONS FOR INDIVIDUAL
Measure #286: Dementia: Counseling Regarding Safety Concerns National Quality Strategy Domain: Patient Safety
Measure #286: Dementia: Counseling Regarding Safety Concerns National Quality Strategy Domain: Patient Safety 2017 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION: Percentage
Measure #195 (NQF 0507): Radiology: Stenosis Measurement in Carotid Imaging Reports National Quality Strategy Domain: Effective Clinical Care
Measure #195 (NQF 0507): Radiology: Stenosis Measurement in Carotid Imaging Reports National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE:
2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
Measure #104 (NQF 0390): Prostate Cancer: Adjuvant Hormonal Therapy for High Risk or Very High Risk Prostate Cancer National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL
Measure #156 (NQF 0382): Oncology: Radiation Dose Limits to Normal Tissues National Quality Strategy Domain: Patient Safety
Measure #156 (NQF 0382): Oncology: Radiation Dose Limits to Normal Tissues National Quality Strategy Domain: Patient Safety 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage
Measure #155 (NQF: 0101): Falls: Plan of Care National Quality Strategy Domain: Communication and Care Coordination
Measure #155 (NQF: 0101): Falls: Plan of Care National Quality Strategy Domain: Communication and Care Coordination 2017 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE: Process This is a two-part
2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #205 (NQF 0409): HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia, Gonorrhea, and Syphilis National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL
2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #109: Osteoarthritis (OA): Function and Pain Assessment National Quality Strategy Domain: Person and Caregiver-Centered Experience and Outcomes 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
Quality ID #39 (NQF 0046): Screening for Osteoporosis for Women Aged Years of Age National Quality Strategy Domain: Effective Clinical Care
Quality ID #39 (NQF 0046): Screening for Osteoporosis for Women Aged 65-85 Years of Age National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE
2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #102 (NQF 0389): Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS
2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Efficiency
Measure #334: Adult Sinusitis: More than One Computerized Tomography (CT) Scan Within 90 Days for Chronic Sinusitis (Overuse) National Quality Strategy Domain: Efficiency and Cost Reduction 2017 OPTIONS
2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #7 (NQF 0070): Coronary Artery Disease (CAD): Beta-Blocker Therapy Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%) National Quality Strategy Domain: Effective
Quality ID #224 (NQF 0562): Melanoma: Overutilization of Imaging Studies in Melanoma National Quality Strategy Domain: Efficiency and Cost Reduction
Quality ID #224 (NQF 0562): Melanoma: Overutilization of Imaging Studies in Melanoma National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE
2) Patients who are 18 years and older with a diagnosis of CAD or history of cardiac surgery who have a prior myocardial infarction
Measure #7 (NQF 0070): Coronary Artery Disease (CAD): Beta-Blocker Therapy Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%) National Quality Strategy Domain: Effective
2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #331: Adult Sinusitis: Antibiotic Prescribed for Acute Viral Sinusitis (Overuse) National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care
Quality ID #249 (NQF 1854): Barrett s Esophagus National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION: Percentage
Measure #154 (NQF: 0101): Falls: Risk Assessment National Quality Strategy Domain: Patient Safety
Measure #154 (NQF: 0101): Falls: Risk Assessment National Quality Strategy Domain: Patient Safety 2017 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE: Process This is a two-part measure which
Quality ID #154 (NQF: 0101): Falls: Risk Assessment National Quality Strategy Domain: Patient Safety
Quality ID #154 (NQF: 0101): Falls: Risk Assessment National Quality Strategy Domain: Patient Safety 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION: Percentage of
2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Efficiency
Quality ID #333: Adult Sinusitis: Computerized Tomography (CT) for Acute Sinusitis (Overuse) National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
Measure #389: Cataract Surgery: Difference Between Planned and Final Refraction - National Quality Strategy Domain: Effective Clinical Care
Measure #389: Cataract Surgery: Difference Between Planned and Final Refraction - National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE:
*NOTE: When submitting CPT code and 99239, it is recommended the measure be submitted each time the code is submitted for hospital discharge.
Quality ID #5 (NQF 0081): Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) National Quality
2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY
Quality ID #113 (NQF 0034): Colorectal Cancer Screening National Quality Strategy Domain: Effective Clinical Care
Quality ID #113 (NQF 0034): Colorectal Cancer Screening National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION:
2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
Measure #192 (NQF 0564): Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures National Quality Strategy Domain: Patient Safety 2016 PQRS OPTIONS FOR
Hepatitis C (HCV) Digestive Health Recognition Program
PQRS #84 Hepatitis C: Ribonucleic Acid (RNA) Effective Clinical Process NQF 0395 Testing Before Initiating Treatment Care Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis
2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Measure #428: Pelvic Organ Prolapse: Preoperative Assessment of Occult Stress Urinary Incontinence National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
Quality ID #236 (NQF 0018): Controlling High Blood Pressure National Quality Strategy Domain: Effective Clinical Care
Quality ID #236 (NQF 0018): Controlling High Blood Pressure National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Intermediate Outcome
Quality ID #117 (NQF 0055): Diabetes: Eye Exam National Quality Strategy Domain: Effective Clinical Care
Quality ID #117 (NQF 0055): Diabetes: Eye Exam National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION: Percentage
Quality ID #1 (NQF 0059): Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%) National Quality Strategy Domain: Effective Clinical Care
Quality ID #1 (NQF 0059): Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%) National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE:
Quality ID #112 (NQF 2372): Breast Cancer Screening National Quality Strategy Domain: Effective Clinical Care
Quality ID #112 (NQF 2372): Breast Cancer Screening National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION: Percentage
Quality ID #119 (NQF 0062): Diabetes: Medical Attention for Nephropathy National Quality Strategy Domain: Effective Clinical Care
Quality ID #119 (NQF 0062): Diabetes: Medical Attention for Nephropathy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process
2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Measure #294: Parkinson s Disease: Parkinson s Disease Medical and Surgical Treatment Options Reviewed National Quality Strategy Domain: Communication and Care Coordination 2017 OPTIONS FOR INDIVIDUAL
Note: This is an outcome measure and will be calculated solely using registry data.
Measure #384: Adult Primary Rhegmatogenous Retinal Detachment Surgery: No Return to the Operating Room Within 90 Days of Surgery National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR
2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Efficiency
Quality ID #419: Overuse Of Neuroimaging For Patients With Primary Headache And A Normal Neurological Examination National Quality Strategy Domain: Efficiency and Cost Reduction 2018 OPTIONS FOR INDIVIDUAL
2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #386: Amyotrophic Lateral Sclerosis (ALS) Patient Care Preferences National Quality Strategy Domain: Person and Caregiver-Centered Experience and Outcomes 2018 OPTIONS FOR INDIVIDUAL MEASURES:
2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome
Measure #258: Rate of Open Repair of Small or Moderate Non-Ruptured Infrarenal Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7) National Quality
Measure #117 (NQF 0055): Diabetes: Eye Exam National Quality Strategy Domain: Effective Clinical Care
Measure #117 (NQF 0055): Diabetes: Eye Exam National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS F INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE: Process DESCRIPTION: Percentage of patients
DENOMINATOR: All patients undergoing anterior or apical pelvic organ prolapse (POP) surgery
Quality ID #428: Pelvic Organ Prolapse: Preoperative Assessment of Occult Stress Urinary Incontinence National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
Quality ID #394 (NQF 1407): Immunizations for Adolescents National Quality Strategy Domain: Community/Population Health
Quality ID #394 (NQF 1407): Immunizations for Adolescents National Quality Strategy Domain: Community/Population Health 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION:
Measure #111 (NQF 0043): Pneumonia Vaccination Status for Older Adults National Quality Strategy Domain: Community/Population Health
Measure #111 (NQF 0043): Pneumonia Vaccination Status for Older Adults National Quality Strategy Domain: Community/Population Health 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION:
Measure #117 (NQF 0055): Diabetes: Eye Exam National Quality Strategy Domain: Effective Clinical Care
Measure #117 (NQF 0055): Diabetes: Eye Exam National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS F INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage of patients 18-75
Note: This is an outcome measure and will be calculated solely using registry data.
Quality ID #303 (NQF 1536): Cataracts: Improvement in Patient s Visual Function within 90 Days Following Cataract Surgery National Quality Strategy Domain: Person and Caregiver-Centered Experience and
2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome
Measure #347 (NQF 1534): Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non- Ruptured Infrarenal Abdominal Aortic Aneurysms (AAA) Who Die While in Hospital National Quality Strategy Domain:
Quality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care
Quality ID #343: Screening Colonoscopy Adenoma Detection Rate National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome DESCRIPTION:
Measure #111 (NQF 0043): Pneumococcal Vaccination Status for Older Adults National Quality Strategy Domain: Community/Population Health
Measure #111 (NQF 0043): Pneumococcal Vaccination Status for Older Adults National Quality Strategy Domain: Community/Population Health 2017 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE: Process
Quality ID #263: Preoperative Diagnosis of Breast Cancer National Quality Strategy Domain: Effective Clinical Care
Quality ID #263: Preoperative Diagnosis of Breast Cancer National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION:
Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety
Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety 2017 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE
Measure #394 (NQF 1407): Immunizations for Adolescents National Quality Strategy Domain: Community/Population Health
Measure #394 (NQF 1407): Immunizations for Adolescents National Quality Strategy Domain: Community/Population Health 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION:
Measure #355: Unplanned Reoperation within the 30 Day Postoperative Period National Quality Strategy Domain: Patient Safety
Measure #355: Unplanned Reoperation within the 30 Day Postoperative Period National Quality Strategy Domain: Patient Safety 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome DESCRIPTION:
2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #134 (NQF 0418): Preventive Care and Screening: Screening for Depression and Follow-Up Plan National Quality Strategy Domain: Community/Population Health 2018 OPTIONS FOR INDIVIDUAL MEASURES:
2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY
Measure #134 (NQF 0418): Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan National Quality Strategy Domain: Community/Population Health 2016 PQRS OPTIONS FOR INDIVIDUAL
Age 18 years and older BMI 18.5 and < 25 kg/m 2
Quality ID #128 (NQF 0421): Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan National Quality Strategy Domain: Community/Population Health 2018 OPTIONS F INDIVIDUAL MEASURES:
2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Measure #204 (NQF 0068): Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
DQA Measure Specifications: Administrative Claims-Based Measures Periodontal Evaluation in Adults with Periodontitis
**Please read the DQA Measures User Guide prior to implementing this measure.** DQA Measure Specifications: Administrative Claims-Based Measures Periodontal Evaluation in Adults with Periodontitis Description:
DESCRIPTION: Percent of asymptomatic patients undergoing CEA who are discharged to home no later than post-operative day #2
Measure #260: Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home by Post-Operative Day #2) National Quality Strategy Domain: Patient Safety
If multiple KRAS mutation tests have been performed, refer to the most recent test results.
Measure #452 (NQF 1860): Patients with Metastatic Colorectal Cancer and KRAS Gene Mutation Spared Treatment with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies National Quality Strategy
**Please read the DQA Measures User Guide prior to implementing this measure.**
**Please read the DQA Measures User Guide prior to implementing this measure.** DQA Measure Technical Specifications: Administrative Claims-Based Measures Prevention: Sealants for 6 9 year-old Children
Quality ID #457 (NQF 0216): Proportion Admitted to Hospice for less than 3 days- National Quality Strategy Domain: Effective Clinical Care
Quality ID #457 (NQF 0216): Proportion Admitted to Hospice for less than 3 days- National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE:
Measure #340 (NQF 2079): HIV Medical Visit Frequency - National Quality Strategy Domain: Efficiency And Cost Reduction
Measure #340 (NQF 2079): HIV Medical Visit Frequency - National Quality Strategy Domain: Efficiency And Cost Reduction 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION:
2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome
Measure #165 (NQF 0130): Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
Measure #260: Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home by Post-Operative Day #2) National Quality Strategy Domain: Patient Safety
Obstructive Sleep Apnea Physician Performance Measurement Set
Obstructive Sleep Apnea Physician Performance Measurement Set Approved by the PCPI September 26, 2008 Co-chairs Patrick Strollo, MD Mark Metersky, MD Work Group Members Richard Berry, MD Philip Becker,
**Please read the DQA Measures User Guide prior to implementing this measure.**
**Please read the DQA Measures User Guide prior to implementing this measure.** DQA Measure Technical Specifications: Administrative Claims-Based Measures Prevention: Topical Fluoride for Children at Elevated
**Please read the DQA Measures User Guide prior to implementing this measure.**
**Please read the DQA Measures User Guide prior to implementing this measure.** DQA Measure Technical Specifications: Administrative Claims-Based Measures Prevention: Topical Fluoride for Children at Elevated
Surveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Measure #127 (NQF 0416): Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention Evaluation of Footwear National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR INDIVIDUAL MEASURES:
Measure #425: Photodocumentation of Cecal Intubation National Quality Strategy Domain: Effective Clinical Care
Measure #425: Photodocumentation of Cecal Intubation National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION: The
DQA Measure Technical Specifications: Administrative Claims-Based Measures Preventive Services for Children at Elevated Caries Risk, Dental Services
**Please read the DQA Measures User Guide prior to implementing this measure.** DQA Measure Technical Specifications: Administrative Claims-Based Measures Preventive Services for Children at Elevated Caries
2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Measure #449 (NQF 1857): HER2 Negative or Undocumented Breast Cancer Patients Spared Treatment with HER2-Targeted Therapies National Quality Strategy Domain: Efficiency and Cost Reduction 2017 OPTIONS
Hepatitis C Adjunct Therapy
Rule Category: Pharmaceutical ` Ref: No: 2016-PH-0002 Version Control: Version No. 1.0 Effective Date: 22-12-2016 Revision Date: 22-12-2017 Table of co Abstract Page Sc Pa Hepatitis C Adjunct Therapy Adjudication
9th Paris Hepatitis Conference
9th Paris Hepatitis Conference Paris, 12 January 2016 Treatment of hepatocellular carcinoma: beyond international guidelines Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow Units
**Please read the DQA Measures User Guide prior to implementing this measure.**
**Please read the DQA Measures User Guide prior to implementing this measure.** DQA Measure Technical Specifications: Administrative Claims-Based Measures: Ambulatory Care Sensitive Emergency Department
Worldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C
Quality ID #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care
Quality ID #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
Worldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
Treatment of and Monitoring for Hepatitis C Virus Infection in Patients with Cirrhosis
Treatment of and Monitoring for Hepatitis C Virus Infection in Patients with Cirrhosis Andrew I. Aronsohn, MD Associate Professor of Medicine University of Chicago Chicago, Illinois Slide 1 of 45 Learning
Surveillance for HCC Who, how Diagnosis of HCC Surveillance for HCC in Practice
Surveillance for Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
AMERICAN GASTROENTEROLOGICAL ASSOCIATION DIGESTIVE HEALTH RECOGNITION PROGRAM IN COLLABORATION WITH CECITY. Non-PQRS Narrative Measure Specifications
AMERICAN GASTROENTEROLOGICAL ASSOCIATION DIGESTIVE HEALTH RECOGNITION PROGRAM IN COLLABORATION WITH CECITY Non-PQRS Narrative Measure Specifications 1 Table of Contents AGA DHRP CRC Measure #1: Colonoscopy
Hepatocellular Carcinoma: Diagnosis and Management
Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm
Screening and Surveillance for Hepatocellular Carcinoma (HCC) Judith Feinberg, MD Project ECHO Jan. 5, 2016
Screening and Surveillance for Hepatocellular Carcinoma (HCC) Judith Feinberg, MD Project ECHO Jan. 5, 2016 Risk Factors for HCC Cirrhosis from any cause is the primary risk factor ~ 80% occur in pts with
OP-10: ABDOMEN CT USE OF CONTRAST MATERIAL
Description of Measure OP-10: ABDOMEN CT USE OF CONTRAST MATERIAL This measure calculates the percentage of abdomen studies that are performed with and without contrast out of all abdomen studies performed
HIV/AIDS DEPARTMENT GLOBAL HEPATITIS PROGRAMME
HIV/AIDS DEPARTMENT GLOBAL HEPATITIS PROGRAMME Technical considerations and case definitions for VIRAL HEPATITIS SURVEILLANCE Dr Yvan J-F Hutin Global Hepatitis Programme 01 FOUR MAIN HEPATITIS VIRUSES
The BlueCompare SM Physician Designation Program
The BlueCompare SM Physician Designation Program Continuing escalation of health care costs has driven premiums and medical expenses to higher and higher levels each year, motivating employers and consumers
Childhood Immunization Status
emeasure Title emeasure Identifier (Measure Authoring Tool) Childhood Immunization Status 117 emeasure Version number 5.1.000 NQF Number 0038 GUID b2802b7a-3580-4be8-9458- 921aea62b78c Measurement Period
Epidemiology and Screening for Hepatitis C Infection
Epidemiology and Screening for Hepatitis C Infection Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Epidemiology/Screening for Hepatitis
Address: City: State: ZIP code: Inferferon Product Requested (Include Strength):
Please complete this entire form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826. This form contains multiple pages. Please complete all pages to avoid a delay in our decision.